Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity

Author： Ibrahim Mohamed A.   El-Sheikh Azza A. K.   Khalaf Hanaa M.   Abdelrahman Aly M.  

Publisher： Informa Healthcare

ISSN： 0892-3973

Source： Immunopharmacology and Immunotoxicology, Vol.36, Iss.2, 2014-04, pp. : 130-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future

By van Raalte Daniel H.   Li Min   Pritchard P. Haydn   Wasan Kishor M.  

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1531-1538

Springer Publishing Company

Access to resources Recommend Favorite

Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-&ggr; (PPAR-&ggr; )

By  

Letters in Drug Design & Discovery, Vol. 5, Iss. 8, 2008-12 ,pp. : 477-480

Bentham Science Publishers

Access to resources Recommend Favorite

Perfluorooctanoic Acid Induced-Developmental Cardiotoxicity: Are Peroxisome Proliferator Activated Receptor α (PPARα) and Bone Morphorgenic Protein 2 (BMP2) Pathways Involved?

By Jiang Qixiao   Lust Robert M.   DeWitt Jamie C.  

Journal of Toxicology and Environmental Health, Vol. 76, Iss. 11, 2013-04 ,pp. : 635-650

Taylor & Francis Ltd

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis

By Giaginis Costas   Margeli Alexandra   Theocharis Stamatios  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 10, 2007-10 ,pp. : 1561-1572

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer

By Fenner Martin H   Elstner Elena  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 557-568

Informa Healthcare

Access to resources Recommend Favorite